Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Ruxolitinib in Preventing Breast Cancer in Patients with High Risk and Precancerous Breast Lesions

This phase II trial studies how well ruxolitinib before surgery works in preventing breast cancer in patients with high risk and precancerous breast conditions. Ruxolitinib may changes the breast cell when administered to participants with precancerous breast conditions. Ruxolitinib may stop the growth of cells by blocking some of the enzymes needed for cell growth.
Breast
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Blinded Drug
Not Available
National
Vanderbilt University
09-30-2019
Treatment
VICCBRE1904
NCT02928978

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Have a breast biopsy showing ADH (atypical ductal hyperplasia), ALH (atypical lobular hyperplasia), LCIS (lobular carcinoma in situ), or DCIS (ductal carcinoma in situ) requiring surgical excision. Microinvasive disease is allowed. The number of participants with DCIS will be limited to no more than 15 in each arm. * NOTE: Tissue from the diagnostic biopsy must be accessible/available for research correlates (i.e., a tissue block or ~10 unstained slides). Due to the nature of the study, fewer slides may be accepted with prior permission from the Protocol Chair if there is insufficient tissue.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: